<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a 55-year-old man complaining of monoparesis of the right arm and <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Brain magnetic resonance imaging (MRI) demonstrated multiple foci of fresh <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The serum <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> was positive, however, the serum anticardiolipin antibody and other autoantibodies indicating <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue diseases</z:e> were negative </plain></SENT>
<SENT sid="3" pm="."><plain>This patient received a diagnosis of primary <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome </plain></SENT>
<SENT sid="4" pm="."><plain>Transcranial Doppler(TCD) monitoring of the middle cerebral artery showed the presence of microembolic signal (<z:chebi fb="28" ids="39005,39010">MES</z:chebi>) </plain></SENT>
<SENT sid="5" pm="."><plain>We initiated <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy with intravenous <z:chebi fb="5" ids="28304">heparin</z:chebi> administration, and three days later we added oral <z:chebi fb="8" ids="10033">warfarin</z:chebi> administration </plain></SENT>
<SENT sid="6" pm="."><plain>We used both <z:chebi fb="8" ids="10033">warfarin</z:chebi> and <z:chebi fb="5" ids="28304">heparin</z:chebi> together for only three days </plain></SENT>
<SENT sid="7" pm="."><plain>The number of <z:chebi fb="28" ids="39005,39010">MES</z:chebi> increased transiently after initiating of <z:chebi fb="8" ids="10033">warfarin</z:chebi> administration, then decreased by <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy with production of an international normalized ratio (INR) of prothrombin time over 2 </plain></SENT>
<SENT sid="8" pm="."><plain>His neurological symptoms normalized except for monoparesis of the right arm </plain></SENT>
<SENT sid="9" pm="."><plain>There were no foci of fresh cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> disclosed on brain MRI performed two months after admission </plain></SENT>
<SENT sid="10" pm="."><plain>The treatment strategy for <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> (APS) patients has not yet been established </plain></SENT>
<SENT sid="11" pm="."><plain>Some reports and guideline recommended that the <z:hpo ids='HP_0001297'>stroke</z:hpo> patients with APS should be treated with long-term oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy, target INR 2.5 (optimal range 2.0 to 3.0) </plain></SENT>
<SENT sid="12" pm="."><plain>In this patient, we confirmed a decrease in the number of <z:chebi fb="28" ids="39005,39010">MES</z:chebi> by <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy with production of INR over 2 </plain></SENT>
<SENT sid="13" pm="."><plain>In APS patients, detection of <z:chebi fb="28" ids="39005,39010">MES</z:chebi> by TCD is a useful device for adjustment of the <z:chebi fb="8" ids="10033">warfarin</z:chebi> dose </plain></SENT>
<SENT sid="14" pm="."><plain>Concerning the course of <z:chebi fb="28" ids="39005,39010">MES</z:chebi> and <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy, transient elevation of the number of <z:chebi fb="28" ids="39005,39010">MES</z:chebi> after initiation of <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy would suggest the <z:hpo ids='HP_0100724'>hypercoagulability</z:hpo> due to an <z:hpo ids='HP_0011009'>acute</z:hpo> decrease in serum protein C level </plain></SENT>
<SENT sid="15" pm="."><plain>Using the TCD technique, we detected such <z:hpo ids='HP_0100724'>hypercoagulability</z:hpo> for the first time </plain></SENT>
</text></document>